Takeda Takes Back Dravet, Lennox-Gastaut Candidate From Ovid
Executive Summary
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
You may also be interested in...
Takeda Charges Into Diversification With ITP Win
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
Ovid Looks To Epilepsy – And Beyond – For Candidate OV350
Ovid anticipates its deal to sell part of its interest in soticlestat milestones and royalties to Ligand will take it through 2026, while it looks to develop its KCC2-targeting OV350 for psychiatric disorders.
Finance Watch: PTC Raises $1bn In Evrysdi Royalty Deal Weeks After Latest Layoffs
Public Company Edition: PTC sold more of its Evrysdi royalties to Royalty Pharma for $1bn. Abivax gained $235.8m in an IPO and concurrent private placement, while Cerevel grossed $450m and Nuvalent and Ultragenyx raised $300m each in follow-on offerings, but Freeline is reviewing strategic options.